Cohance to invest Rs. 23 crore on cGMP Oligonucleotide facility at Hyderabad
This strategic investment strengthens Cohance's integrated oligonucleotide platform
This strategic investment strengthens Cohance's integrated oligonucleotide platform
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
Subscribe To Our Newsletter & Stay Updated